Hezhong Chen

机构：Second Military Medical University, Changhai Hospital · ORCID：0000-0003-1774-8229

发表论文 106 篇 · 总被引 2338 次 · h-index 28

代表论文

• Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma (2022 · Journal for ImmunoTherapy of Cancer · 被引 283)
• Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma (2021 · Annals of Surgery · 被引 202)
• Robot-assisted Versus Conventional Minimally Invasive Esophagectomy for Resectable Esophageal Squamous Cell Carcinoma: Early Results of a Multicenter Randomized Controlled Trial: the RAMIE Trial. (2022 · PubMed · 被引 89)
• The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study (2022 · Cancer Immunology Immunotherapy · 被引 61)
• A novel prognostic mRNA/miRNA signature for esophageal cancer and its immune landscape in cancer progression (2021 · Molecular Oncology · 被引 61)
• Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study (2023 · Journal of Thoracic and Cardiovascular Surgery · 被引 53)